December 2016

December 2016

Velindre NHS Trust Metastatic Breast Cancer (MBC) Service Development

JW Partners: Velindre NHS Trust and Novartis Pharmaceuticals
Project Name: Velindre NHS Trust Metastatic Breast Cancer (MBC) Service Development

Joint working project summary:
The collaborative approach with Novartis within the remit of a partnership project scheme will support the development of the Velindre NHS Trust Metastatic Breast Cancer (MBC) Service Development.

The objective of  the new MBC service development will be to ensure treatment optimisation for MBC patients within the  Trust by:

  1. Improving MBC patient care by:
    -  stratifying patients into different models of care dependent on their needs (this will include MBC patients being treated within Velindre Cancer Centre or in their local outreach hospital in South East Wales);
    - increasing MBC patient concordance and adherence to therapy through additional support;
    - establishing oral SACT dedicated clinics and implementing local guidelines;
    - improving treatment pathway for oral SACT MBC patients across South East Wales by adhering to local guidelines and links into the multi-disciplinary team MDT;
     
  2. Improving patient experience and satisfaction by providing an oral SACT dedicated contact  to ensure all patients  receive the appropriate information and support at the key points in the treatment pathway
     
  3. Sharing ongoing project outcomes and  knowledge with other site specific MBC NHS Oral  SACT services developments and local, regional, national & international healthcare meetings. This will ensure that Velindre Cancer Centre can utilise the combined knowledge and experience to build on their reputation as a centre of excellence in the treatment of MBC whilst empowering other healthcare organisations to aspire to the same level of excellence  
     
  4. Capturing service data to demonstrate the new models of care (Non-Medical Prescriber Led clinic) in MBC is benefitting patients and is financially sustainable for the Trust.

Expected patient outcomes for this project

Outcome 1: Improve the patients’ clinical journey by developing a dedicated patient pathway for oral SACT patients.

Outcome 2: Improved MBC patient care, experience, satisfaction, concordance and adherence to therapy by developing a new MBC service in South East Wales that is patient-centric and focused on the individual needs and requirements of relevant patients treated with oral SACT.

Outcome 3: To improve training and development of the MBC service that can ensure early access of newly introduced oral SACT to MBC patients and build on a reputation of a centre of excellence for MBC.

Outcome 4: Demonstrate service sustainability to the Trust.

Start Date & Duration: 5th December 2016 – 30th April  2019
Project period: 29 months

NHS Greater Glasgow & Clyde Molecular Diagnostic Pathway Development

JW Partners: NHS Greater Glasgow & Clyde, Novartis Pharmaceuticals UK Limited and Celgene Limited

Joint working project summary: This Joint Working Project aims to introduce new molecular techniques into routine clinical practice. The project aims at achieving the following objectives:

  1. Identify companion or stand-alone diagnostics for introduction in patient pathways across Scotland and to inform on the current Scottish process to approve companion or stand-alone diagnostics for the relevant medicines
  2. Develop pathways across Scotland incorporating:
    - relevant companion or stand-alone diagnostics as identified in the course of the Project; efficient and effective sequential testing strategies such as the introduction of Next Generation Sequencing (“NGS”) and other novel - technologies to routine practice
  3. Provide the regional molecular pathology laboratories in Scotland with means of test validation for diagnostic tools to support new pathways by sharing relevant information developed in the course of the Project;
  4. Highlight the impact on patients access to medicines and companion diagnostic tools  of medicines supported by the process developed in the course of the Project:
  5. Develop protocols, which support genetic testing for entry of patients in clinical trials, in collaboration with WoSCAN clinicians and the NHS GG&C Clinical trials unit.
  6. Educate the wider community of academia, NHS and pharmaceutical industry on the benefits of increasing access to medicines’ relevant diagnostics tests for patients and show the value of stakeholder’s collaboration of this project to gain support to further develop the  service developed in the course of the Project.

Expected patient outcomes for this project:

The Project extension shall aim at furthering and consolidating the objectives already achieved through the Project in the previous year, and namely improving patient outcomes by incorporating a prognostic and diagnostic tool in the relevant patient pathways across Scotland, for specific drugs to be identified, by optimising the use of medicines in suitable patients.

Start Date & Duration: January 2015
Amendment agreement: December 2016
Project period: 12 months
Project end date: December 2017

 

ONC17-C001 January 2017